FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945441372> ?p ?o ?g. }

• W2945441372 endingPage "483" @default.
• W2945441372 startingPage "481" @default.
• W2945441372 abstract "In 1945, Drs Bernhard Zondek and Yehuda Bromberg demonstrated intradermal treatment with estrone and estradiol benzoate induced urticarial lesions in some patients.1Zondek B. Bromberg Y.M. Endocrine allergy.J Allergy. 1945; 16: 1-16Abstract Full Text PDF Scopus (42) Google Scholar Fifty years later, Shelley et al,2Shelley W.B. Shelley E.D. Talanin N.Y. et al.Estrogen dermatitis.J Am Acad Dermatol. 1995; 32: 25-31Abstract Full Text PDF PubMed Scopus (80) Google Scholar who introduced the concept of progesterone dermatitis several decades prior, defined estrogen dermatitis based on studies of 7 women with premenstrual flares of skin eruptions including papulovesicular, urticarial, or eczematous lesions or generalized pruritus. Previously described therapies for estrogen dermatitis include estrogen desensitization, tamoxifen, leuprolide, and oophorectomy.3Perdue N. Ezra N. Mousdicas N. Estrogen dermatitis presenting as gyrate erythema treated with leuprolide.Dermatitis. 2014; 25: 277-278Google Scholar Here we report a case of estrogen-induced dermatitis successfully treated with omalizumab. We previously described the case of a 37-year-old woman who presented with a longstanding history (>10 years) of a waxing and waning polymorphous eruption consisting of symmetrically distributed migratory pruritic and occasionally painful arcuate erythematous plaques involving the medial aspects of the breasts consistent with a gyrate erythema (Fig 1) as well as urticarial plaques scattered on the trunk and extremities.3Perdue N. Ezra N. Mousdicas N. Estrogen dermatitis presenting as gyrate erythema treated with leuprolide.Dermatitis. 2014; 25: 277-278Google Scholar Flares regularly began on or near day 2 of menses, and lasted for approximately 2 weeks.3Perdue N. Ezra N. Mousdicas N. Estrogen dermatitis presenting as gyrate erythema treated with leuprolide.Dermatitis. 2014; 25: 277-278Google Scholar Intradermal injections (0.1 mL) of conjugated estrogen (100 μg), medroxyprogesterone (100 μg), histamine, and normal saline were administered to the patient's forearm.3Perdue N. Ezra N. Mousdicas N. Estrogen dermatitis presenting as gyrate erythema treated with leuprolide.Dermatitis. 2014; 25: 277-278Google Scholar Estrogen and histamine injection sites were positive for wheal formation within 15 minutes, but no reaction was seen in the progesterone or saline injection sites.3Perdue N. Ezra N. Mousdicas N. Estrogen dermatitis presenting as gyrate erythema treated with leuprolide.Dermatitis. 2014; 25: 277-278Google Scholar Based on the clinical presentation and skin testing, estrogen dermatitis was diagnosed. This condition did not respond to an oral antihistamine regimen of 10 mg cetirizine daily and 10 to 20 mg of hydroxyzine nightly. Although significant improvement was seen with a 6-month course of leuprolide, (11.25-mg injections every 3 months), the response was incomplete, and leuprolide was subsequently discontinued when the patient underwent an elective hysterectomy and bilateral oophorectomy for symptomatic uterine fibroids.3Perdue N. Ezra N. Mousdicas N. Estrogen dermatitis presenting as gyrate erythema treated with leuprolide.Dermatitis. 2014; 25: 277-278Google Scholar Despite this surgery, the patient's estrogen dermatitis persisted. Given lack of or insufficient control provided by the therapies mentioned above, the patient, at 41 years of age (body mass index, 34 kg/m2), elected to begin treatment with omalizumab, 150 mg subcutaneously every 4 weeks. Treatment with omalizumab rapidly cleared the patient's estrogen dermatitis, which has now been well controlled with monthly omalizumab infusions for 2 years. In asthma, use and dosing of omalizumab are determined by body weight and total serum IgE; however, total serum IgE and body weight are not used to guide use or dosing of omalizumab for chronic idiopathic urticaria, for which dosing options are 150 mg or 300 mg every 4 weeks. Based on this finding, baseline IgE measurements were not obtained in our patients, and the lower dose (150 mg) was chosen with the plan to increase if needed. The pathophysiology of estrogen-induced urticarial eruptions and dermatitis remains to be defined. In addition to demonstrating that intradermal estrogen administration could induce urticarial eruptions in patients, Zondek and Bromberg1Zondek B. Bromberg Y.M. Endocrine allergy.J Allergy. 1945; 16: 1-16Abstract Full Text PDF Scopus (42) Google Scholar reported that serum from estrogen-sensitive patients could induce similar skin reaction in naïve patients. These investigators also found that heating serum from estrogen-sensitive patients to 56°C prior to passive transfer reduced the severity of these urticarial eruptions, leading the investigators to suggest these eruptions were antibody dependent.3Perdue N. Ezra N. Mousdicas N. Estrogen dermatitis presenting as gyrate erythema treated with leuprolide.Dermatitis. 2014; 25: 277-278Google Scholar The cyclical course of our patient's skin eruption in relation to menses, coupled with positive intradermal testing to estrogen and the urticarial component to the eruption led us to hypothesize her estrogen dermatitis might represent a type of IgE-mediated hypersensitivity reaction, which was the basis for a therapeutic trial of omalizumab. Omalizumab is a neutralizing IgG monoclonal antibody that binds free circulating IgE. This binding inhibits IgE from binding its high-affinity Fc receptor on the surface of mast cells and basophils. Currently, omalizumab is approved for the treatment of chronic idiopathic urticaria and asthma with some efficacy extending into other IgE-mediated diseases.4Sanchez J. Ramirez R. Diez S. et al.Omalizumab beyond asthma.Allergol Immunopathol (Madr). 2012; 40: 306-315Crossref PubMed Scopus (15) Google Scholar The fact that the patient's cutaneous manifestations improved after treatment with omalizumab suggests that this condition is mediated by a hypersensitivity reaction involving IgE. From the standpoint of a type I hypersensitivity reaction, the insufficiency of antihistamines to control our patient's skin eruption suggests other mediators could be involved in the pathogenesis of estrogen dermatitis. Preformed mast cell–derived mediators that could also contribute include granule-stored polyamines, proteoglycans, proteases, lysosomal enzymes, and cytokines.5Moon T.C. Befus A.D. Kulka M. Mast cell mediators: their differential release and the secretory pathways involved.Front Immunol. 2014; 5: 569Crossref PubMed Scopus (249) Google Scholar Additionally, activation of the Fc receptor could stimulate mast cell de novo synthesis and release of other mediators including cytokines, prostaglandins, and reactive oxygen species. Although classically implicated in type I hypersensitivity reactions, IgE can also alter T-cell function through engagement of the high-affinity IgE receptor on dendritic cells suggesting a potential for IgE to contribute to type IV hypersensitivity reactions in some settings.6Maurer D. Fiebiger E. Reininger B. et al.Fcε receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S dependent pathway of MHC Class II Presentation.J Immunol. 1998; 161: 2731-2739PubMed Google Scholar The ability of IgE to contribute to different types of hypersensitivity reactions (ie, immediate and delayed types) could explain the polymorphous nature of this patient's estrogen dermatitis (ie, gyrate erythema and urticaria). Another notable aspect of this case was that the patient's estrogen dermatitis was refractory to oophorectomy. The persistence of the patient's estrogen dermatitis was surprising (as the ovaries are the primary producers of estrogen) and prompted us to consider other potential sources of this hormone.2Shelley W.B. Shelley E.D. Talanin N.Y. et al.Estrogen dermatitis.J Am Acad Dermatol. 1995; 32: 25-31Abstract Full Text PDF PubMed Scopus (80) Google Scholar Our patient's body mass index was 34 kg/m2; considering the association of increased estrogen levels with greater adiposity, it is possible that her estrogen dermatitis persisted because of peripheral aromatases in the fat converting adrenal gland–derived androgens into estradiol.7Hetemäki N. Savolainen-Peltonen H. Tikkanen M.J. et al.Estrogen metabolism in abdominal subcutaneous and visceral adipose tissue in postmenopausal women.J Clin Endocrinol Metab. 2017; 102: 4588-4595Google Scholar If this is the case, reducing adiposity through weight reduction would also be a therapeutic consideration to manage estrogen dermatitis. Other possible sources of estrogens to consider in this case would include residual ovarian tissue present after oophorectomy or dietary or environmental exposures. Phytoestrogens, naturally present in soy and grains, and phthalates, commonly found in plastics associated with food storage and household items, are structurally similar to endogenous estrogen.8Anwer F. Chaurasia S. Khan A.A. Hormonally active agents in the environment: a state-of-the-art review.Rev Environ Health. 2016; 31: 415-433Google Scholar We present a case of estrogen dermatitis responsive to omalizumab. The unique treatment approach and favorable response for this patient may shed light on the pathophysiology of this condition. More specifically, this case supports a role for IgE in pathogenesis and suggests that omalizumab should be considered in the therapeutic ladder for estrogen dermatitis." @default.
• W2945441372 created "2019-05-29" @default.
• W2945441372 creator A5027747620 @default.
• W2945441372 creator A5030811708 @default.
• W2945441372 creator A5031798985 @default.
• W2945441372 creator A5048993887 @default.
• W2945441372 creator A5077727360 @default.
• W2945441372 creator A5085056520 @default.
• W2945441372 date "2019-06-01" @default.
• W2945441372 modified "2023-09-27" @default.
• W2945441372 title "Treatment of estrogen-induced dermatitis with omalizumab" @default.
• W2945441372 cites W2092346711 @default.
• W2945441372 cites W2165854070 @default.
• W2945441372 cites W2168342927 @default.
• W2945441372 cites W2322905533 @default.
• W2945441372 cites W2506109653 @default.
• W2945441372 cites W2760456888 @default.
• W2945441372 cites W4252566856 @default.
• W2945441372 doi "https://doi.org/10.1016/j.jdcr.2019.03.007" @default.
• W2945441372 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6536736" @default.
• W2945441372 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31193571" @default.
• W2945441372 hasPublicationYear "2019" @default.
• W2945441372 type Work @default.
• W2945441372 sameAs 2945441372 @default.
• W2945441372 citedByCount "0" @default.
• W2945441372 crossrefType "journal-article" @default.
• W2945441372 hasAuthorship W2945441372A5027747620 @default.
• W2945441372 hasAuthorship W2945441372A5030811708 @default.
• W2945441372 hasAuthorship W2945441372A5031798985 @default.
• W2945441372 hasAuthorship W2945441372A5048993887 @default.
• W2945441372 hasAuthorship W2945441372A5077727360 @default.
• W2945441372 hasAuthorship W2945441372A5085056520 @default.
• W2945441372 hasBestOaLocation W29454413721 @default.
• W2945441372 hasConcept C126322002 @default.
• W2945441372 hasConcept C141105273 @default.
• W2945441372 hasConcept C159654299 @default.
• W2945441372 hasConcept C16005928 @default.
• W2945441372 hasConcept C203014093 @default.
• W2945441372 hasConcept C2777164284 @default.
• W2945441372 hasConcept C2778564945 @default.
• W2945441372 hasConcept C71924100 @default.
• W2945441372 hasConceptScore W2945441372C126322002 @default.
• W2945441372 hasConceptScore W2945441372C141105273 @default.
• W2945441372 hasConceptScore W2945441372C159654299 @default.
• W2945441372 hasConceptScore W2945441372C16005928 @default.
• W2945441372 hasConceptScore W2945441372C203014093 @default.
• W2945441372 hasConceptScore W2945441372C2777164284 @default.
• W2945441372 hasConceptScore W2945441372C2778564945 @default.
• W2945441372 hasConceptScore W2945441372C71924100 @default.
• W2945441372 hasFunder F4320306127 @default.
• W2945441372 hasIssue "6" @default.
• W2945441372 hasLocation W29454413721 @default.
• W2945441372 hasLocation W29454413722 @default.
• W2945441372 hasLocation W29454413723 @default.
• W2945441372 hasLocation W29454413724 @default.
• W2945441372 hasLocation W29454413725 @default.
• W2945441372 hasOpenAccess W2945441372 @default.
• W2945441372 hasPrimaryLocation W29454413721 @default.
• W2945441372 hasRelatedWork W1984486579 @default.
• W2945441372 hasRelatedWork W2326375297 @default.
• W2945441372 hasRelatedWork W2738981461 @default.
• W2945441372 hasRelatedWork W2899204639 @default.
• W2945441372 hasRelatedWork W2954190961 @default.
• W2945441372 hasRelatedWork W3029088939 @default.
• W2945441372 hasRelatedWork W3091639260 @default.
• W2945441372 hasRelatedWork W3189133770 @default.
• W2945441372 hasRelatedWork W4224227857 @default.
• W2945441372 hasRelatedWork W4297184974 @default.
• W2945441372 hasVolume "5" @default.
• W2945441372 isParatext "false" @default.
• W2945441372 isRetracted "false" @default.
• W2945441372 magId "2945441372" @default.
• W2945441372 workType "article" @default.